{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:19:01Z","timestamp":1767845941980,"version":"3.49.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.ygyno.2009.09.005","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T08:17:01Z","timestamp":1254903421000},"page":"497-503","source":"Crossref","is-referenced-by-count":13,"title":["Application of proteomics in ovarian cancer: Which sample should be used?"],"prefix":"10.1016","volume":"115","author":[{"given":"Isabelle","family":"Cadron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toon","family":"Van Gorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Amant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Waelkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignace","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl. 1","key":"10.1016\/j.ygyno.2009.09.005_bib1","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynaecological Cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ygyno.2009.09.005_bib2","unstructured":"Chemotherapy for gynaecologic neoplasms. Current therapy and novel approaches. R Angioli, PB Panici, JJ Kavanagh, S Pecorelli, M Penalver. Marcel Dekker publications 2004."},{"key":"10.1016\/j.ygyno.2009.09.005_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"Jacobs","year":"2004","journal-title":"Mol Cell Proteomics"},{"issue":"12","key":"10.1016\/j.ygyno.2009.09.005_bib4","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.5858\/2002-126-1518-PATTMD","article-title":"Proteomic approaches to tumor marker discovery","volume":"126","author":"Rai","year":"2002","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.ygyno.2009.09.005_bib5","first-page":"511","article-title":"Lysophosphatidic acid: an ovarian cancer marker","volume":"29","author":"Sedl\u00e1kov\u00e1","year":"2008","journal-title":"Eur J Gynaecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2009.09.005_bib6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2009.09.005_bib7","unstructured":"Van Gorp T, Daemen A, Cadron I, Despierre E, Aman F, Timmerman D, et al. Validation of the Risk of Ovarian Malignancy Algorithm (ROMA) using HE4 and CA125 in an independent prospective study. Abstract at 16th International Meeting of the European Society for Gynaecological Oncology in Belgrade, Servia."},{"issue":"4","key":"10.1016\/j.ygyno.2009.09.005_bib8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1158\/1078-0432.CCR-07-1569","article-title":"Diagnostic markers for early detection of ovarian cancer","volume":"14","author":"Visintin","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.005_bib9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/1097-0142(19930115)71:2<430::AID-CNCR2820710225>3.0.CO;2-S","article-title":"The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays","volume":"71","author":"Ward","year":"1993","journal-title":"Cancer"},{"issue":"6884","key":"10.1016\/j.ygyno.2009.09.005_bib10","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/bmj.306.6884.1030","article-title":"Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography","volume":"306","author":"Jacobs","year":"1993","journal-title":"BMJ"},{"issue":"9160","key":"10.1016\/j.ygyno.2009.09.005_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(98)10261-1","article-title":"Screening for ovarian cancer: a pilot randomised controlled trial","volume":"353","author":"Jacobs","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ygyno.2009.09.005_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"Jacobs","year":"2004","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"10.1016\/j.ygyno.2009.09.005_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1470-2045(09)70026-9","article-title":"Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"10","author":"Menon","year":"2009","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2009.09.005_bib14","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(09)70072-5","article-title":"Screening for ovarian cancer: not yet there","volume":"10","author":"Vergote","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2009.09.005_bib15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(02)07746-2","article-title":"Use of proteomic patterns in serum to identify ovarian cancer","volume":"359","author":"Petricoin","year":"2002","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.ygyno.2009.09.005_bib16","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/pmic.200500358","article-title":"Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly available database","volume":"5","author":"Omenn","year":"2005","journal-title":"Proteomics"},{"issue":"13","key":"10.1016\/j.ygyno.2009.09.005_bib17","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1002\/pmic.200401219","article-title":"Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display","volume":"5","author":"Tammen","year":"2005","journal-title":"Proteomics"},{"issue":"4","key":"10.1016\/j.ygyno.2009.09.005_bib18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1373\/clinchem.2006.080101","article-title":"Pre-analytic influence of sample handling on SELDI-TOF serum protein profiles","volume":"53","author":"Timms","year":"2007","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.ygyno.2009.09.005_bib19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/bioinformatics\/btg484","article-title":"Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments","volume":"20","author":"Baggerly","year":"2004","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ygyno.2009.09.005_bib20","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(02)09389-3","article-title":"Letter to the editor","volume":"360","author":"Elwood","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2009.09.005_bib21","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0140-6736(02)09390-X","article-title":"Letter to the editor","volume":"360","author":"Diamandis","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ygyno.2009.09.005_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1074\/mcp.R400007-MCP200","article-title":"Mass spectrometry as a diagnostic and a cancer biomarker discovery tool","volume":"3","author":"Diamandis","year":"2004","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.005_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1535-6108(02)00037-5","article-title":"The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics","volume":"1","author":"Daly","year":"2002","journal-title":"Cancer cell"},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.005_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1677\/erc.0.0110163","article-title":"High-resolution serum proteomic features for ovarian cancer detection","volume":"11","author":"Conrads","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ygyno.2009.09.005_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1677\/erc.1.00868","article-title":"High-resolution serum proteomic patterns for ovarian cancer detection","volume":"11","author":"Baggerly","year":"2004","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2009.09.005_bib26","first-page":"2904","article-title":"Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry","volume":"9","author":"Ye","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ygyno.2009.09.005_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bjc.6601882","article-title":"Proteomic based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer","volume":"91","author":"Ahmed","year":"2004","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/j.ygyno.2009.09.005_bib28","doi-asserted-by":"crossref","first-page":"12343","DOI":"10.1073\/pnas.2033602100","article-title":"Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis","volume":"100","author":"Kozak","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.ygyno.2009.09.005_bib29","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1002\/pmic.200500093","article-title":"Characterization of serum biomarkers for detection of early stage ovarian cancer","volume":"5","author":"Kozak","year":"2005","journal-title":"Proteomics"},{"issue":"3","key":"10.1016\/j.ygyno.2009.09.005_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1349-7006.2005.00029.x","article-title":"Identification of haemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer","volume":"96","author":"Woong-Shick","year":"2005","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ygyno.2009.09.005_bib31","doi-asserted-by":"crossref","first-page":"5882","DOI":"10.1158\/0008-5472.CAN-04-0746","article-title":"Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer","volume":"64","author":"Zhang","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2009.09.005_bib32","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1002\/pmic.200401321","article-title":"Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer","volume":"5","author":"Ahmed","year":"2005","journal-title":"Proteomics"},{"issue":"4","key":"10.1016\/j.ygyno.2009.09.005_bib33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1631\/jzus.2005.B0227","article-title":"An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer","volume":"6B","author":"Yu","year":"2005","journal-title":"JZUS"},{"key":"10.1016\/j.ygyno.2009.09.005_bib34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ygyno.2005.08.051","article-title":"Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer","volume":"100","author":"Kong","year":"2006","journal-title":"Gyn Oncol"},{"key":"10.1016\/j.ygyno.2009.09.005_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2005.11.029","article-title":"Biomarker discovery for ovarian cancer using SELDI-TOF MS","volume":"102","author":"Zhang","year":"2006","journal-title":"Gyn Oncol"},{"key":"10.1016\/j.ygyno.2009.09.005_bib36","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1525-1438.2007.01139.x","article-title":"Serum proteomic patterns for ovarian cancer monitoring","volume":"18","author":"Helleman","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"24","key":"10.1016\/j.ygyno.2009.09.005_bib37","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1158\/1078-0432.CCR-07-0747","article-title":"Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer","volume":"13","author":"Jackson","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ygyno.2009.09.005_bib38","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1373\/clinchem.2006.080721","article-title":"A novel high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples","volume":"53","author":"Lopez","year":"2007","journal-title":"Clin Chem"},{"issue":"14","key":"10.1016\/j.ygyno.2009.09.005_bib39","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1002\/pmic.200401205","article-title":"Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1","volume":"5","author":"Moshkovskii","year":"2005","journal-title":"Proteomics"},{"issue":"suppl 1","key":"10.1016\/j.ygyno.2009.09.005_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1525-1438.2006.00475.x","article-title":"Plasma proteomic pattern as biomarkers for ovarian cancer","volume":"16","author":"Lin","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2009.09.005_bib41","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1021\/bi027184+","article-title":"Temperature range of thermodynamic stability for the native state of reversible tow stat proteins","volume":"42","author":"Kumar","year":"2003","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.005_bib42","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/1078-0432.CCR-05-0461","article-title":"Proteomic based discovery and characterization of glycosylated eosinophil derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine","volume":"12","author":"Ye","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2009.09.005_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/00016340802443830","article-title":"Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology","volume":"88","author":"Petri","year":"2009","journal-title":"Acta Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2009.09.005_bib44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2007.04.022","article-title":"Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment","volume":"106","author":"Badgwell","year":"2007","journal-title":"Gyn Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2009.09.005_bib45","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/1078-0432.CCR-05-2516","article-title":"Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling","volume":"12","author":"Davidson","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2009.09.005_bib46","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/1522-2683(200209)23:18<3168::AID-ELPS3168>3.0.CO;2-A","article-title":"A protein molecular weight map of ES2 clear cell ovarian carcinoma cells using a two-dimensional liquid separations\/mass mapping technique","volume":"23","author":"Wang","year":"2002","journal-title":"Electrophoresis"},{"key":"10.1016\/j.ygyno.2009.09.005_bib47","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/pmic.200300763","article-title":"Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate biomarkers","volume":"4","author":"Wang","year":"2004","journal-title":"Proteomics"},{"key":"10.1016\/j.ygyno.2009.09.005_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1477-5956-5-16","article-title":"Comparative proteome analysis of human epithelial ovarian cancer","volume":"5","author":"Gagn\u00e9","year":"2007","journal-title":"Proteome Sci"},{"key":"10.1016\/j.ygyno.2009.09.005_bib49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2005.04.002","article-title":"Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies","volume":"98","author":"He","year":"2005","journal-title":"Gyn Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2009.09.005_bib50","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1021\/pr060402r","article-title":"Identification of platinum resistant associated proteins through proteomic analysis of human ovarian cancer cells and their platinum resistant sub lines","volume":"6","author":"Yan","year":"2007","journal-title":"J Proteome Res"},{"issue":"3","key":"10.1016\/j.ygyno.2009.09.005_bib51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1074\/mcp.M500140-MCP200","article-title":"Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels","volume":"5","author":"Stewart","year":"2006","journal-title":"Mol Cell Proteomics"},{"issue":"7","key":"10.1016\/j.ygyno.2009.09.005_bib52","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1172\/JCI27698","article-title":"Serine protease HtrA1 modulates chemotherapy induced cytotoxicity","volume":"116","author":"Chien","year":"2006","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.ygyno.2009.09.005_bib53","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1002\/pmic.200500925","article-title":"Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10","volume":"6","author":"Le Moguen","year":"2006","journal-title":"Proteomics"},{"key":"10.1016\/j.ygyno.2009.09.005_bib54","doi-asserted-by":"crossref","unstructured":"Song J, Shih IeM, Salani R, Chan DW, Zhang Z. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res 2007; 13(22) Nov 15; 13: 6842-6849.","DOI":"10.1158\/1078-0432.CCR-07-0569"},{"key":"10.1016\/j.ygyno.2009.09.005_bib55","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1126\/science.274.5289.998","article-title":"Laser capture microdissection","volume":"274","author":"Emmert-Buck","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2009.09.005_bib56","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/(SICI)1522-2683(19990101)20:4\/5<689::AID-ELPS689>3.0.CO;2-J","article-title":"The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis\u2014preliminary findings","volume":"20","author":"Banks","year":"1999","journal-title":"Electrophoresis"},{"key":"10.1016\/j.ygyno.2009.09.005_bib57","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.0.CO;2-A","article-title":"Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines","volume":"21","author":"Ornstein","year":"2000","journal-title":"Electrophoresis"},{"key":"10.1016\/j.ygyno.2009.09.005_bib58","first-page":"2541","article-title":"Normal, benign, preneoplastic and malignant prostate cells have distinct protein expression profiles resolved by SELDI MS","volume":"8","author":"Cazares","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2009.09.005_bib59","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1002\/pmic.200300466","article-title":"Application of laser capture microdissection combined with two dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma","volume":"3","author":"Shekouh","year":"2003","journal-title":"Proteomics"},{"key":"10.1016\/j.ygyno.2009.09.005_bib60","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1158\/0008-5472.CAN-03-3807","article-title":"A technical triade for proteomic identification and characterization of cancer biomarkers","volume":"64","author":"Melle","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2009.09.005_bib61","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/mp.54.4.253","article-title":"Application of laser capture microdissection and proteomics in colon cancer","volume":"54","author":"Lawrie","year":"2001","journal-title":"J Clin Pathol: Mol Pathol"},{"key":"10.1016\/j.ygyno.2009.09.005_bib62","unstructured":"Cadron I, Van Gorp T, Amant F, Vergote I, Moerman Ph, Waelkens E, et al. The use of laser microdissection and SELDI-TOF MS in ovarian cancer tissue to identify protein profiles. Anticancer Res. 2009 Apr;29(4):1039-45."},{"key":"10.1016\/j.ygyno.2009.09.005_bib63","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1021\/ac061613i","article-title":"Membrane proteome analysis of microdissected ovarian tumor tissues using capillary isoelectric focusing\/reversed phase liquid chromatography tandem MS","volume":"79","author":"Wang","year":"2007","journal-title":"Anat Chem"},{"key":"10.1016\/j.ygyno.2009.09.005_bib64","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/1615-9861(200201)2:1<76::AID-PROT76>3.0.CO;2-O","article-title":"Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer","volume":"2","author":"Jones","year":"2002","journal-title":"Proteomics"},{"issue":"5","key":"10.1016\/j.ygyno.2009.09.005_bib65","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1021\/pr050461p","article-title":"Comparative proteomics of ovarian epithelial tumors","volume":"5","author":"An","year":"2006","journal-title":"J Proteome Res"},{"issue":"3","key":"10.1016\/j.ygyno.2009.09.005_bib66","first-page":"233","article-title":"Discovery of altered protein profiles in epithelial ovarian carcinogenesis by SELDI mass spectrometry","volume":"29","author":"Luo","year":"2008","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1016\/j.ygyno.2009.09.005_bib67","doi-asserted-by":"crossref","unstructured":"Bengtsson S, Krogh M, Szigyarto CA, Uhlen M, Schedvins K, Silfversw\u00e4rd C, et al. Large-scale proteomics analysis of human ovarian cancer for biomarkers. J Proteome Res 2007; 6: 1440-1450.","DOI":"10.1021\/pr060593y"},{"key":"10.1016\/j.ygyno.2009.09.005_bib68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2008.10.019","article-title":"Proteomic identification of tumor-associated protein in ovarian serous cystadenocarcinoma","volume":"275","author":"Li","year":"2009","journal-title":"Cancer Letters"},{"key":"10.1016\/j.ygyno.2009.09.005_bib69","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF02899685","article-title":"Peroxisomes in human colon carcinomas. A cytochemical and biochemical study","volume":"62","author":"Cable","year":"1992","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"10.1016\/j.ygyno.2009.09.005_bib70","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s004320050246","article-title":"Decreased expression of the peroxisomal bifunctional enzyme and carbonyl reductase in human hepatocellular carcinomas","volume":"125","author":"Suto","year":"1999","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809006763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809006763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T23:04:33Z","timestamp":1633993473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809006763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S0090825809006763"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.09.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}